000			02189cam a2200349 a 4500
003			EG-GiCUC
005			20250223031732.0
008			170613s2016 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.08.M.Sc.2016.Mo.P
100	0		_aMohamed Ahmed Emad Abdellatif Elgendy
245	1	2	_aA pharmaceutical study on improving the solubility of an antihypertensive drug / _cMohamed Ahmed Emad Abdellatif Elgendy ; Supervised Omaima Naim Elgazayerly , Mina Ibrahim Tadros , Mona Ibrahim Abdeltawab Elassal
246	1	5	_aدراسة صيدلة علي زيادة الذوبان لعقار مضاد لارتفاع ضغط الدم
260			_acairo : _bMohamed Ahmed Emad Abdellatif El-Gendy , _c2016
300			_a136 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aHypertension is a major health problem worldwide, yet remains under- diagnosed and under-treated, it is also considered as the most prevalent and powerful contributor for cardiovascular (CV) diseases worldwide. It is mostly accompanied with other risk factors such as dyslipidaemia, insulin resistance, glucose intolerance and obesity. CV diseases lead to serious events such as myocardial infarction and stroke which has been labelled as the most important {u2017}hypertension related{u2018} complication which contributes to the premature death of millions of people each year. The primary goal of hypertension management is to achieve the maximum reduction in the long-term total risk of cardiovascular morbidity and mortality
530			_aIssued also as CD
653		4	_aMixed micelles
653		4	_aOlmesartan Medoxomil
653		4	_aOral bioavailability
700	0		_aMina Ibrahim Tadros , _eSupervisor
700	0		_aMona Ibrahim Abdeltawab Elassal , _eSupervisor
700	0		_aOmaima Naim Elgazayerly , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c61202 _d61202